55 results about "Lactobacillus helveticum" patented technology

The invention relates to the field of bioengineering, in particular to an enzyme composition, a product and application of the enzyme composition in preparation of Ectoine. The invention provides an enzyme composition. The enzyme composition comprises a mutant of 2-hydroxy-4-aminobutyric acid oxidase, a mutant of keto transaminase, a mutant of hydroperoxide hydrolase, a mutant of Ectoine synthetase, a mutant of pyruvic acid-CoA oxidase and lactobacillus helveticus lactic dehydrogenase. According to the method disclosed by the invention, a plurality of mutant enzymes are utilized for combined transformation for the first time, and cheap 2-hydroxy-4-aminobutyric acid is taken as a starting raw material to quickly and efficiently produce Ectoine; the enzyme method has the characteristics of easiness in control, short conversion time, few generated impurities and the like, so that the method has unique advantages in the aspects of low-cost and large-scale mass production of Ectoin.

The invention relates to application of lactobacillus helveticus HH-LPH17 in preparation of medicine for assisting in relieving inflammatory bowel diseases and relates to the technical field of probiotic compositions.The probiotic composition for treating the inflammatory bowel diseases comprises, by weight, 10 parts to 80 parts of lactobacillus johnsonii LBJ 456, 10 parts to 60 parts of lactobacillus helveticus HH-LPH17, 10 parts to 60 parts of lactobacillus acidophilus HH-LA26 and 10 parts to 60 parts of bifidobacterium longum HH-BL18. The composition comprises the following components in parts by weight: 10-60 parts of bifidobacterium bifidum HH-BB27 and 10-60 parts of bifidobacterium longum subspecies infantis HH-BI27. According to the probiotic composition for treating the inflammatory bowel disease, probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating the inflammatory bowel disease is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of the inflammatory bowel disease.

The invention relates to a probiotic composition for treating rheumatoid arthritis and application thereof, and relates to the technical field of probiotic compositions.The probiotic composition for treating rheumatoid arthritis is prepared from, by weight, 10-40 parts of lactobacillus johnsonii LBJ 456, 10-30 parts of lactobacillus helveticus HH-LPH17 and 10-30 parts of lactobacillus acidophilus HH-LA26. The bifidobacterium longum subsp. Longum HH-BL18, the bifidobacterium bifidum HH-BB27 and the bifidobacterium longum subsp. Infantis HH-BI27 are prepared from the following raw materials in parts by weight: 10 to 40 parts of bifidobacterium longum subsp. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating rheumatoid arthritis is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of RA.

The invention discloses a preparation method and application of micromolecular oat beta-glucan, and the preparation method comprises the following steps: inoculating lactobacillus into a fermentation substrate composed of oat bran and water, and carrying out fermentation culture and sterilization to obtain the micromolecular oat beta-glucan, wherein the lactobacillus is composed of lactobacillus helveticus and lactobacillus plantarum, and the viable count ratio of the lactobacillus helveticus to the lactobacillus plantarum is 1: (0.5-2). The lactobacillus fermentation is utilized to improve the utilization rate of the oat bran and reduce the loss of active ingredients, so that the preparation method has the advantages of low cost, low energy consumption, environmental friendliness and the like, and can be directly used as an additive for preparing facial masks, essence or toner; the prepared product is superior to a product prepared by a traditional method in the aspects of DPPH free radical scavenging capacity, total antioxidant capacity, cytotoxicity, total sugar content, anti-inflammatory performance, molecular weight and the like, and has a good market application prospect.

The invention belongs to the technical field of microbiological detection, and discloses a PCR primer combination for detecting mixed microorganisms in a food fermentation process and a detection method thereof. The primer combination comprises a primer pair used for detecting pediococcus pentosaceus, a primer pair used for detecting plant lactobacillus, a primer pair used for detecting lactobacillus mucus fermentation, a primer pair used for detecting bacillus amyloliquefaciens and a primer pair used for detecting lactobacillus acidophilus. The primer pair is at least one of a primer pair for detecting lactobacillus helveticus and a primer pair for detecting acetobacter pasteurianus. The primer combination or the kit containing the primer combination can realize species level specific detection of microorganisms, and can be used for qualitatively / quantitatively detecting food and key functional microorganisms in the food fermentation process, so that the dynamic change of a target flora in the fermentation process is quickly and accurately monitored.

The invention discloses a method for fermenting seriola quinqueradiata meat rich in probiotics, and belongs to the technical field of biological fermentation by utilizing bacterial strains to ferment aquatic products. According to the invention, a strain of lactobacillus plantarum and a strain of lactobacillus helveticus are used; the inoculated fermentation can change the community composition of microorganisms in the fermentation process of the seriola quinqueradiata, reduce the growth of other spoilage microorganisms and inhibit the spoilage of the seriola quinqueradiata. Lactobacillus plantarum and lactobacillus helveticus are respectively compared and are used as a production fermentation agent to ferment the seriola quinqueradiata meat, and through sensory evaluation, physicochemical index evaluation and safety evaluation in the seriola quinqueradiata meat fermentation process, the improvement effect of inoculation fermentation on the quality and flavor of the seriola quinqueradiata meat is researched. By utilizing the method, the seriola quinqueradiata meat fermentation product with better meat quality and flavor can be obtained.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus helveticus YM1922 for promoting brain development, improving concentration and nourishing nerves as well as a metabolite, a complex flora, a metabolite and application. The lactobacillus helveticus YM1922 is preserved in the China General Microbiological Culture Collection Center on September 10, 2024, and the preservation number of the lactobacillus helveticus YM1922 is CGMCC No. 31928. Fermentation metabolites of the strain can promote secretion of brain-derived neurotrophic factors, and thalli can inhibit production of intestinal tract D-gluconic acid in intestinal tracts. Therefore, the strain and the metabolite thereof have application potentials of promoting brain development, improving cognitive level, improving concentration and nourishing nerves, and can be prepared into products for playing corresponding roles.

The invention discloses a strain for preventing and treating Parkinson's disease as well as a composition, application and a product thereof, and relates to the technical field of microorganisms. The invention provides three strains from human milk, namely lactobacillus helveticus LV-20, plant lactobacillus LPP8 and lactobacillus fermentum PL-15, the invention further provides a composition capable of preventing and treating the Parkinson's disease, and the three strains can well prevent and treat the Parkinson's disease and can be used for preventing and treating the Parkinson's disease. The composition can significantly improve dyskinesia (such as static tremor, muscle stiffness, movement retardation, posture balance and the like), reduce neuron damage, significantly reduce alpha-syn deposition, reverse sensory function degradation and cognitive disorder, relieve sleep disorder, inhibit neuroinflammation and oxidative stress, reduce and repair intestinal barrier damage, relieve gastrointestinal dysfunction, and improve the curative effect. As probiotics or synbiotics, products for treating and preventing Parkinson's disease have a wide application prospect.

The invention discloses a lactobacillus helveticus metaplasm complex and application thereof in constipation treatment, and relates to the technical field of constipation treatment, a specific lactobacillus helveticus KLDS 1.1 1105 strain is adopted, and metaplasm is prepared through fermentation and spray drying. The invention further provides a three-layer embedded compound structure. The outer layer is composed of pitaya powder and prune powder and is used for rapidly relaxing the bowels; the middle layer contains a pomegranate peel extract and is used for regulating flora; the core is colon-targeted lactobacillus helveticus metagen and inulin and is used for long-acting regulation. According to the compound, through the multi-target synergistic effect, gastrointestinal hormone is regulated, related signal channels are activated, the function of intestinal pace-making cells is promoted, and generation of short-chain fatty acid is increased, so that the constipation symptom is rapidly relieved, meanwhile, the intestinal function is fundamentally repaired, and the intestinal microecology is improved. The product disclosed by the invention is good in stability, high in safety and suitable for preparing medicines or functional foods for treating functional constipation.

The invention relates to a probiotic composition for promoting alcohol degradation and metabolism and improving discomfort symptoms after drinking. The probiotic composition comprises the following raw materials in parts by weight: 35-40 parts of lactitol; 28 to 35 parts of fructo-oligosaccharide; 15 to 34 parts of stachyose; 5-10 parts of mango fruit powder; 2 to 4 parts of lactobacillus rhamnosus LR519; 0.5 to 2.5 parts of plant lactobacillus LP45 (Lipoprotein 45); 0.005 to 0.015 part of bifidobacterium bifidum B11, and 0.005 to 0.015 part of bacillus subtilis; 0.005 to 0.015 part of Lactobacillus helveticus L551, and 0.005 to 0.015 part of Lactobacillus And 0.1 to 0.3 part of vitamin C. The traditional Chinese medicine composition can promote alcohol degradation, accelerate alcohol metabolism and effectively improve discomfort symptoms after drinking.

The invention discloses lactobacillus helveticus 5-1 separated from fermented milk and application of the lactobacillus helveticus 5-1. The lactobacillus helveticus 5-1 has the highest viable count in 12 hours at the end of the logarithmic phase; the lactobacillus helveticus 5-1 has better acid production capacity and acid resistance; the tolerance of the lactobacillus helveticus 5-1 is strong under the bile salt concentration of 0.3%; the thallus extract of the lactobacillus helveticus 5-1 has strong capability of removing DPPH (1, 1-diphenyl-2-picrylhydrazyl); the lactobacillus helveticus 5-1 is high in exopolysaccharide (EPS) production capacity. The lactobacillus helveticus 5-1 with high activity, strong oxidation resistance, excellent acid and cholate resistance and high exopolysaccharide yield is separated, screened and cultured from the traditional fermented milk in Xinjiang, so that the blank of multifunctional and high-performance autonomous strains in the prior art is filled; the application efficiency and the stability of the compound in probiotic preparations and functional foods are improved.

The present invention provides an immunologic stimulant which contains Lactobacillus helveticus, and wherein the Lactobacillus helveticus has three functions: the activation of dendritic cell-like cells, the induction of the production of immunoglobulin A (IgA), and the induction of the production of interleukin-12 (IL-12).

The present invention provides a compound probiotic for enhancing immunity and a functional yogurt prepared therefrom. The compound probiotic is composed of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024. In the present invention, three strains with different properties, namely Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024, are combined in a certain proportion, and a synergistic effect is generated among the three strains, which has significant technical advantages in enhancing immunity. The product of the present invention has high safety, is not prone to generating resistance, and has good safety and application prospects.

The invention discloses lactobacillus helveticus CCFM1440 for regulating and controlling secretion of IL-10 (interleukin-10) in a host kidney and improving kidney health and a metagen of the lactobacillus helveticus CCFM1440, and belongs to the technical field of microorganisms. The screened Lactobacillus helveticus CCFM1440 and the metagen thereof have the capacity of increasing secretion of IL-10 in the kidney of a host so as to assist in relieving kidney injury, can remarkably improve acute nephritis and kidney injury, reduce the content of creatinine and urea nitrogen in serum of an individual suffering from acute kidney injury, reduce the level of inflammatory markers in kidney tissue of the individual suffering from acute kidney injury, and can be used for treating acute nephritis and kidney injury. The oxidative stress injury of an acute kidney injury individual is relieved, and the application prospect is huge.

The invention discloses a preparation method of armillaria luteo-virens fermentation broth with an anti-aging effect and application of the armillaria luteo-virens fermentation broth in cosmetics, and the preparation method specifically comprises the following steps: inoculating lactobacillus into a fermentation substrate, and carrying out fermentation culture and sterilization to obtain the armillaria luteo-virens fermentation broth. The fermentation substrate comprises armillaria luteo-virens sporocarp and water; wherein the lactobacillus is composed of lactobacillus helveticus and lactobacillus paracasei, and the viable count ratio of the lactobacillus helveticus to the lactobacillus paracasei is 1: (0.5-2). The active ingredients in the armillaria luteo-virens sporocarp are extracted in a lactic acid bacteria fermentation mode, loss of the active ingredients can be reduced, and the skin care effect of the armillaria luteo-virens can be better exerted; the prepared armillaria luteo-virens sporocarp fermentation liquor can be directly used as a cosmetic and can also be added into a cosmetic basic formula for use, the product safety is high, the effects of resisting oxidation and repairing damaged cells are achieved, and a certain cell growth promoting effect is achieved.

The present invention addresses the problem of providing a composition, for activating plasmacytoid dendritic cells, which has a high level of safety and can be taken by a large number of people more easily. A composition for activating plasmacytoid dendritic cells according to the present invention contains one or more lactic acid bacteria selected from Lactobacillus lactic acid bacteria (excluding Lactobacillus helveticus), Lacticaseibacillus lactic acid bacteria, and lactic acid bacteria belonging to Streptococcus thermophilus. It is to be noted that the above-mentioned composition for activating plasmacytoid dendritic cells preferably contains Lactobacillus lactic acid bacteria (excluding Lactobacillus helveticus), Lacticaseibacillus lactic acid bacteria, and lactic acid bacteria belonging to Streptococcus thermophilus.

The present invention relates to the use of the Lactobacillus helveticus BGRA43 strain for the prevention and / or treatment of liver diseases and / or liver disorders, preferably metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (N AFLD), and / or for the reduction of liver steatosis. The formulation, preferably for peroral administration, comprising the L. helveticus BGRA43 strain. The formulation comprising the L helveticus BGRA43 strain, which is preferably a probiotic food product intended for human consumption. Lyophilizate of the L helveticus BGRA43 strain, comprising the L. helveticus BGRA43 strain at a concentration from 108 to 1013 CFU / g.

The application discloses a bifendate biomimetic oral nanodelivery system based on lactobacillus helveticus exosomes and a preparation method and application thereof. The preparation method comprises the following steps: extracting lactobacillus helveticus exosomes from a lactobacillus helveticus culture solution by adopting a method combining continuous differential centrifugation and microporous membrane filtration; and mixing the lactobacillus helveticus exosomes with bifendate, and performing ultrasonic treatment and incubation treatment to prepare the lactobacillus helveticus exosome-bifendate biomimetic oral nanodelivery system. The application successfully extracts a lactobacillus helveticus source exosome with high yield and expandable advantages for the first time, and improves the clinical limitations of high cost and low productivity of animal source and plant source exosomes as oral delivery carriers; meanwhile, the prepared lactobacillus helveticus exosome-bifendate biomimetic oral nanodelivery system combines the natural characteristics of exosomes and the high biological safety of probiotics, and can realize the balance between the oral delivery performance and the biological safety of the nanocarrier.

The invention relates to a probiotic composite product for improving emotion and a preparation method of the probiotic composite product. The probiotic composite product comprises the following probiotic components: lactobacillus helveticus R0052, lactobacillus plantarum R1012 and bifidobacterium longum R0175. The combination of the three probiotics has a synergistic effect, and can reduce the ratio of kynurenine / tryptophan in a human body and reduce metabolic kynurenine. The probiotic composition can also reduce cortisol and adrenal gland levels, relieve depression and improve mood.

The invention discloses lactobacillus helveticus capable of relieving rheumatoid arthritis and application of the lactobacillus helveticus, and belongs to the technical field of microorganisms. A strain of lactobacillus helveticus CCFM1501 is screened out, the lactobacillus helveticus CCFM1501 can produce cell wall protease, amino-peptidase and aromatic transaminase at high yield, and has the effect of relieving rheumatoid arthritis, and the specific effects are that the thickness of a posterior claw of a rat with rheumatoid arthritis is reduced, and knee joint injury is improved; the content of proinflammatory cytokines in the serum of rheumatoid arthritis rats is reduced, the content of anti-inflammatory cytokines IL-10 in the serum of the rheumatoid arthritis rats is increased, the content of arthritis specific antibodies in the serum of the rheumatoid arthritis rats is reduced, the mRNA relative expression quantity of colonic tight junction proteins ZO-1 and Occludin in the rheumatoid arthritis rats is increased, and the anti-inflammatory activity of the rheumatoid arthritis rats is improved. The content of acetic acid and butyric acid in excrement of rats with rheumatoid arthritis is increased.

The present application provides an immunostimulant containing Lactobacillus helveticus, wherein the Lactobacillus helveticus has three functions: activation of dendritic cell-like cells, induction of immunoglobulin A (IgA) production, and induction of interleukin-12 (IL-12) production.

The invention belongs to the field of microorganisms, and particularly provides application of Lactobacillus helveticus ZJUIDS11: relieving and improving ozostomia (breath), and also provides application of the Lactobacillus helveticus ZJUIDS11 as well as application of the Lactobacillus helveticus ZJUIDS11 as an anti-inflammatory agent. The preservation number of the lactobacillus helveticus ZJUIDS11 is CGMCC (China General Microbiological Culture Collection Center) NO.24761, and the preservation number of the lactobacillus helveticus ZJUIDS11 is CGMCC NO.24761. The lactobacillus helveticus ZJUIDS11 can be used for inhibiting hydrogen sulfide and methyl mercaptan.

The invention discloses lactobacillus helveticus IMAU16360 with ACE (Angiotensin Converting Enzyme) inhibitory activity and application of the lactobacillus helveticus IMAU16360 in fermented milk, and belongs to the field of microorganisms. The lactobacillus helveticus IMAU16360 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.36567, the preservation time is November 11, 2025, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The commercial leavening agent PYS-010 and the lactobacillus helveticus IMAU16360 are compounded according to the ratio of 1: 1, the pH and acidity change trend of the compounded group in the storage period is consistent with that of a control group, the compounded group is fused into an existing process system, and an existing production line does not need to be replaced; the elasticity and viscosity of a single strain fermented product are improved, so that the product is fuller in taste; on the premise that the basic taste is not influenced, the fermented milk has ACE inhibitory activity; meanwhile, a relatively high level of viable count is maintained, and good market value is achieved.

The present disclosure relates to compositions and methods useful for dietary augmentation to provide therapeutic intervention for the amelioration of symptoms associated with rosacea-prone skin. According to one embodiment of the present disclosure, there is provided an orally administrable composition containing a therapeutically effective amount of: (a) a probiotic blend of bacterial components containing at least: (i) Lactobacillus helveticus, (ii) Lactobacillus plantarum, (iii) Bifidobacterium longum, and (iii) Streptococcus thermophilus; and (b) at least one plant-based, antioxidant-rich source of fiber.

This invention relates to the field of health food, and discloses a high-yield direct-inoculation starter culture for antihypertensive peptides and its application in the preparation of antihypertensive yogurt. The starter culture is prepared by mixing *Streptococcus thermophilus* WHH1590, *Lactobacillus delbrueckii* subsp. bulgaricus WHH699, and *Lactobacillus helveticus* WHH2580 in a ratio of 90-100:15-25:1. This starter culture, after mixing, exhibits a significant synergistic effect, significantly enhancing the ability of microorganisms to decompose proteins and significantly increasing the content of antihypertensive peptides in yogurt. When using the starter culture of this application to ferment yogurt, it achieves the technical advantages of a short fermentation cycle, high yield of antihypertensive peptides, and high ACE inhibitory activity. Yogurt prepared with the starter culture provided by this application not only ensures a high yield of antihypertensive peptides but also possesses excellent sensory qualities, with a thick texture, delicate structure, and no unpleasant flavor. Yogurt prepared with the starter culture provided by this application exhibits higher thermal stability and safety compared to existing technologies.

Provided in the present application are a compound probiotic for preventing and treating colitis, and the use thereof. The compound probiotic for preventing and treating colitis consists of a Pediococcus acidilactici PA53 strain and a Lactobacillus helveticus LH76 strain. The two probiotics can cooperate with each other, boost each other, and achieve a synergistic effect in terms of preventing and treating colitis, which is specifically exhibited in alleviating the weight loss caused by colitis, reducing the disease activity index, restoring colon length, ameliorating inflammatory factor dysregulation and oxidative stress response caused by colitis, and increasing the content of short-chain fatty acids in the intestines. In a case where the same bacterial dosage is used, the compounding of the two strains exhibits significantly improved efficacy in preventing and treating colitis compared with strain interventions using either strain alone.

The invention discloses a complex microbial inoculant for camel milk fermentation and application of the complex microbial inoculant. The complex microbial inoculant is prepared from the following strains in parts by weight: 1 to 10 parts of lactobacillus plantarum KC28, 20 to 50 parts of leuconostoc mesenteroides SHU1396, 0.1 to 0.5 part of lactobacillus acidophilus DSM9126, 1 to 10 parts of lactobacillus helveticus R0052 and 10 to 20 parts of kluyveromyces marxianus D53749. According to the complex microbial inoculant for camel milk fermentation, through selection of various strains, camel milk fermentation can be rapidly achieved, the fermentation time is short, and the fermented camel milk after fermentation is pure in taste, sour, light in sweet taste, heavy in milk flavor, free of mutton smell and fishy smell and excellent in flavor and taste.

The invention belongs to the technical field of microorganisms, and particularly relates to a synbiotics preparation of lactobacillus helveticus as well as a preparation method and application of the synbiotics preparation. The synbiotics preparation of the lactobacillus helveticus, provided by the invention, is a microcapsule preparation prepared by taking the lactobacillus helveticus as probiotics and sialylated breast milk oligosaccharide as prebiotics and sequentially embedding by adopting sodium alginate and chitosan; wherein the lactobacillus helveticus is lactobacillus helveticus HL88. The lactobacillus helveticus HL88 adopted by the invention has better cracking activity on the sialylated breast milk oligosaccharide, and can effectively improve the utilization efficiency of the sialylated breast milk oligosaccharide. Furthermore, the lactobacillus helveticus and the sialylated breast milk oligosaccharide are subjected to composite embedding, so that the synergistic metabolism effect can be achieved, and the brain development process is effectively promoted. Therefore, the invention can provide a treatment thought for improving the brain development retardation, and can also provide a technical basis for developing probiotic medicines for promoting brain development.

The invention relates to leuconostoc mesenteroides capable of assisting weight management and application, a product and a method thereof, and relates to the technical field of probiotic compositions.The probiotic composition for improving obesity is prepared from, by weight, 10-60 parts of lactobacillus rhamnosus PB-LR76, 10-60 parts of lactobacillus helveticus HH-LPH17, 10-80 parts of lactobacillus casei PB-LC39 and 10-60 parts of lactobacillus fermentum HH-LF392. The feed additive comprises the following components in parts by weight: 10-60 parts of leuconostoc mesenteroides subsp. Mesenteroides MUM502 and 10-60 parts of lactobacillus reuteri PB-LR09. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for improving obesity is prepared, and a safe and effective new method is provided for weight management of obese people.